Will the pharmaceutical industry enter the stagflation channel?!

The pharmaceutical industry has encountered three big shock waves in succession, which may lead to stagflation First of all, the tax burden is heavy after the transition to the two ticket system, the capital flow is becoming slower and slower, and the return period of some enterprises has been more than half a year, or even longer Some enterprises have not passed on national policies to customers at all levels, and the basic tax points collected from customers are far higher than the national regulations The return period is also long, which causes serious advance of customers At the same time, the whole payment must be delivered, which will greatly reduce the liquidity and return rate of the industry, and further affect the stability of market sales and supply Some large enterprises have a large number of products and redundant processing flow After the implementation of the two vote system, some large products cannot be satisfied due to financial processing, and the sales volume has been halved In the case of new drugs, as a general drug whose profit is calculated by the angle of market Porter, it is also worse Secondly, the consistency evaluation 4 + 7 price negotiation has an unprecedented lethality In addition to the better profit space and sales price of some products, other products have plummeted in a straight line Many winning enterprises have disbanded the sales team, cut off the agency customers and directly connected the terminals A large number of defaulted markets and customers bring extreme instability to the market Due to the decrease of product profit, the number of product maintenance personnel is greatly reduced, and the terminal service and promotion are also weakened The enterprises have evolved into the processing factories and suppliers of medical institutions, and the specialized medical marketing has been increasingly impacted Different from the past, the raw material enterprises that rarely sell pharmaceutical products, the original research enterprises that have never sold a product in China, and the new declaration enterprises that have no reputation may suddenly overtake in ignorance, and become the black horse and the troublemaker killed in the low price competition in the market Many brand enterprises are in the process of falling Many years of R & D investment and huge market investment are in zero moment, which brings great impact and influence to the industry, enterprises, employees, cooperative customers and even the majority of shareholders and investors Thirdly, can more and more strict financial and tax management and clinical examination, especially the recent key examination of 77 representative enterprises, completely eliminate the operation mode that the industry has been forced to do for many years, change the trend that medical institutions are always going to be higher and higher, and eat and take cards, reduce the market investment cost of the industry and enterprises, and truly benefit the people? Can the industry survive? Will the speed of capital flow be further reduced? Will the products available for sale be further reduced? Will enterprises and customers operate in reverse? From the perspective of operating income, due to the two vote system, the industry seems to be still in good shape, but in addition to all costs and taxes, the production enterprises and customers have been operating at a low profit rate for a long time The gross profit of the total investment in algebra in China is no more than 2-3 yuan, saving the cost of starting algebra in 100000 yuan, and the gross profit is no more than 1 yuan The processing fee of 1-2 yuan or gross profit of the production enterprise is also very good, which is far from the huge profit industry imagined by the outside world who does not know the industry very well Many problems may be common in the industry The R & D and market input costs are increasing, the raw material cost, labor cost, financial cost and time cost are increasing rapidly, but the bid price is getting lower and lower The consistency evaluation is more direct shock therapy, and leek cutting has changed the life of competing products But whether it will bring effective reduction of patients' actual medical costs, or whether it will change in the same way as when the medical bonus is cancelled The rapid rise of examination fees, consumables fees, operation fees and other costs far exceeds the reduction of the medical bonus part, which remains to be evaluated and evaluated scientifically in time If we can give more warm support and guidance to the industry and enterprises as well as the employees and customers in the most difficult time of the industry, we will have a long history of depression for the industry and other industries We will improve the standardized management level of the industry, effectively reduce the burden for the industry and enterprises, speed up capital turnover, jointly maintain stability, and provide industry and industry people More hope and dawn, medical people will ensure the safety of drug use, ensure the supply of drug market, bring more new drugs and good drugs to the public, shorten the gap between the level of drug use and developed countries, and help medical institutions popularize product knowledge and drug safety with professional services and promotion, so as to give back to the society and the people As the article said, many problems are common in the industry We have been deeply involved in the medical circle for many years, and we believe that there must be many different views and feelings! Welcome to share——